Sodelglitazar

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameSodelglitazar
Drug Alias Name索格列扎sodelglitazarumGW-677954677954GSK-677954
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator activated receptor agonists
TargetsPeroxisome proliferator activated receptor
Therapy Area/IndicationsMetabolic SyndromeDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsMetabolic SyndromeDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG